Net Sales and Key Asset Performance Further, O'Grady said "Looking at the first quarter, net sales came in at $26.0 million, and we are tracking to our full year net product sales and adjusted EBITDA ...

Advancing commercial readiness efforts with a planned Q1 2026 launch of Anaphylm, subject to FDA approval "In the first quarter of 2025, we achieved a major milestone for Aquestive with the submission ...